

DATE: September 22, 2022

SUBJECT: COVID-19 Vaccine Administration Billing Guidelines
Billing Information for COVID-19 Vaccine Administration Fees

Provider Qualifications

AHCCCS and its Contractors shall reimburse for the COVID-19 vaccine administration fee(s) to the following AHCCCS registered providers:

- Pharmacies obtaining the vaccine directly from the federal government, and
- The Arizona Department of Health Services (ADHS) COVID-19 on-boarded providers.

This includes pharmacies when the vaccine is administered by a pharmacist or intern and technicians under the supervision of a pharmacist, who are currently licensed and certified by the Arizona State Board of Pharmacy consistent with the limitations of state law A.R.S §32-1974.

Reimbursement Rates

AHCCCS Contractors and the AHCCCS Fee-For-Service Program shall reimburse providers the following rates for the COVID-19 vaccine administration fees:

Dates of service 12/14/2020 through 3/14/2021

- Initial vaccine administration - \$16.94
- Second vaccine administration - \$28.39
- Single dose vaccine administration - \$28.39

Dates of service 3/15/2021 through 8/8/2021

- Initial vaccine administration - \$40.00
- Second vaccine administration - \$40.00
- Single dose vaccine administration - \$40.00

Dates of service 8/9/2021 and after

- Initial vaccine administration - \$83.00
- Second vaccine administration - \$83.00
- Single dose vaccine administration - \$83.00

Provider Claim Requirements

- COVID-19 vaccines are provided at no charge from the federal government at this time. Therefore, when billing for the vaccine itself, a cost for the vaccine greater than zero shall **not** be entered on the CMS 1500 claim form, in the 837P format or Pharmacy POS formats.
- Non-Pharmacy Providers must use the NPI(s) of the ordering and rendering provider on the CMS 1500 medical claim form or in the 837P format when billing for the vaccine administration fee. The ordering and rendering provider(s) must be registered with AHCCCS.
- CPT codes to be used for claims submission for COVID-19 Vaccines and Administration are specific to the vaccine being administered; therefore, the NDC is not required when using the CMS 1500 medical form or the 837P format.
- Pharmacies must submit the National Provider Identifier (NPI) of the pharmacy as the ordering and rendering provider on the claim. The ordering and rendering provider(s) must be registered with AHCCCS.
- Pharmacy claims for administration of the COVID-19 vaccines may be submitted through the point-of-sale (POS) system following the guidelines from the National Council for Prescription Drug Programs (NCPDP) and as outlined below.

- Retroactive billing will be allowed for the administration of the Pfizer COVID-19 vaccination back to dates of service 12/14/20, for the Moderna COVID-19 vaccine administration back to dates of service 12/18/20, and for the Janssen COVID-19 vaccine administration back to dates of service 2/27/2021.

Managed Care Organization (MCO) Requirements

MCOs must suspend network requirements and reimburse for the COVID-19 vaccine administered by all qualified providers. AHCCCS MCO Contractors shall require providers to submit claims for reimbursement of the COVID-19 vaccine administration fee using the CMS 1500 medical form, in the 837P format or through the point-of-sale (POS) system.

AHCCCS Provider types that can be reimbursed for the COVID-19 Vaccination Administration

All providers submitting claims for the administration fee for COVID-19 vaccines must use the CMS 1500 claim form or the 837P format.

- 02 Hospital
- 03 Pharmacy
- 05 Clinic
- 06 Emergency Ground Transportation
- 08 MD
- 09 CNM
- 10 Podiatrist
- 18 PA
- 19 RNP
- 20 Respiratory Therapist
- 22 Nursing Home
- 23 Home Health Agency
- 29 Community Rural Health
- 31 DO
- 41 Dialysis Clinic
- C2 FQHC
- C5 638 FQHC
- IC Integrated Clinic
- TR Treat and Refer

American Medical Association (AMA) Current Procedural Terminology (CPT) for Medical Claims and NDC Codes for Pharmacy Claims for COVID-19 Vaccines and Administration Fees are below:

CPT Vaccine Codes for Medical Claims	Vaccine - Procedure Name	Vaccine Descriptor	Vaccine NDC Codes for Pharmacy POS Claims	Minimum Dosing Interval (general guidelines)	AHCCCS Payment
91300	Pfizer-BioNTech Covid-19 Vaccine (Comirnaty)	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]) vaccine, mRNA LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use.	59267-1000-01 vial 59267-1000-02 carton 59267-1000-03 diluent		\$.00

0001A	Pfizer-BioNTech COVID-19 Vaccine / Comirnaty (First Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted: first dose	59267-1000-01 vial 59267-1000-02 carton 59267-1000-03 diluent		\$16.94 for dates of service prior to 3/15/2021 ; \$40.00 for dates of service through 8/8/2021 ; \$83.00 for dates of service 8/9/2021 and after.
0002A	Pfizer-BioNTech COVID-19 Vaccine / Comirnaty (Second Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted: second dose	59267-1000-01 vial 59267-1000-02 carton 59267-1000-03 diluent	21 days after the initial dose	\$28.39 for dates of service prior to 3/15/2021 ; \$40.00 for dates of service through 8/8/2021 ; \$83.00 for dates of service 8/9/2021 and after.
0003A	Pfizer-BioNTech COVID-19 Vaccine / Comirnaty (Third Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted: third dose	59267-1000-01 vial 59267-1000-02 carton 59267-1000-03 diluent	Recommended population per CDC 28 days or more after second dose	\$40.00 for dates of service 8/1/2021 through 8/8/2021 ; \$83.00 for dates of service 8/9/2021 and after
0004A	Pfizer-BioNTech COVID-19 Vaccine / Comirnaty (Booster)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted: booster dose	59267-1000-01 vial 59267-1000-02 carton 59267-1000-03 diluent	Refer to FDA/CDC guidance	\$40.00 for dates of service 8/1/2021 through 8/8/2021 ; \$83.00 for dates of service 8/9/2021 and after
91305	Pfizer-BioNTech COVID-19 Vaccine	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, tris-sucrose formulation, for intramuscular use	59267-1025-01		\$.00

0051A	Pfizer-BioNTech COVID-19 Vaccine (First Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose	59267-1025-01		\$83.00 for dates of service 01/03/2022 and after
0052A	Pfizer-BioNTech COVID-19 Vaccine (Second Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose	59267-1025-01	21 days after first dose	\$83.00 for dates of service 01/03/2022 and after
0053A	Pfizer-BioNTech COVID-19 Vaccine (Third Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose	59267-1025-01	2nd Dose to 3rd Dose (CDC recommended population[s] [e.g., immunocompromised]): 28 or More Days	\$83.00 for dates of service 01/03/2022 and after
0054A	Pfizer-BioNTech COVID-19 Vaccine (Booster)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose	59267-1025-01	Booster: Refer to FDA/CDC Guidance	\$83.00 for dates of service 01/03/2022 and after
91307	Pfizer-BioNTech COVID-19 Vaccine	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	59267-1055-01 vial		\$.00

0071A	Pfizer-BioNTech COVID-19 Vaccine (First Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation: first dose	59267-1055-01 vial		\$83.00 for dates of service 10/29/2021 and after
0072A	Pfizer-BioNTech COVID-19 Vaccine (Second Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation: second dose	59267-1055-01 vial	1st Dose to 2nd Dose: 21 Days	\$83.00 for dates of service 10/29/2021 and after
0073A	Pfizer-BioNTech COVID-19 Vaccine (Third Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation: third dose	59267-1055-01	2nd Dose to 3rd Dose (CDC recommended population[s] [e.g., immunocompromised]) 28 or More Days	\$83.00 for dates of service 03/01/2022 and after
0074A	Pfizer-BioNTech COVID-19 Vaccine (Booster)	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	59267-1025-01	Booster: Refer to FDA/CDC Guidance	\$83.00 for dates of service 5/17/2022 and after
91308	Pfizer-BioNTech COVID-19 Vaccine	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNALNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent	59267-0078-01 59267-0078-04		\$.00

		reconstituted, tris-sucrose formulation, for intramuscular use			
0081A	Pfizer-BioNTech COVID-19 Vaccine (First Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	59267-0078-01 59267-0078-04		\$83.00 for dates of service 6/17/2022 and after
0082A	Pfizer-BioNTech COVID-19 Vaccine (Second dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	59267-0078-01 59267-0078-04	1st Dose to 2nd Dose: 21 Days	\$83.00 for dates of service 6/17/2022 and after
0083A	Pfizer-BioNTech COVID-19 Vaccine (Third dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; Third dose	59267-0078-01 59267-0078-04	3rd Dose: Refer to FDA/CDC Guidance	\$83.00 for dates of service 6/17/2022 and after
91312		Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, trissucrose formulation, for intramuscular use	59267-0304-01 59267-1404-01		\$.00
0124A		Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus	9267-0304-01 59267-1404-01	Refer to FDA/CDC Guidance	\$83.00 for dates of service 08/31/2022 and after

		disease [COVID-19] vaccine, mRNA-LNP, bivalent spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, booster dose			
91315	Pfizer-BioNTech COVID-19 Bivalent	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19] vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	59267-0565-01		\$.00
0154A	Pfizer-BioNTech COVID-19 Bivalent (Booster)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19] vaccine, mRNA-LNP, bivalent spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, booster dose	59267-0565-01	Refer to FDA/CDC Guidance	\$83.00 for dates of service 08/31/2022 and after
91301	Moderna Covid-19 Vaccine	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19] vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	80777-0273-10 vial 80777-0273-99 carton		\$.00
0011A	Moderna Covid-19 Vaccine Administration (First Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19] vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; first dose	80777-0273-10 vial 80777-0273-99 carton		\$16.94 for dates of service prior to 3/15/2021 ; \$40.00 for dates of service through 08/08/2021 ; \$83.00 for dates of service 8/9/2021 and after.
0012A	Moderna Covid-19 Vaccine Administration	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus	80777-0273-10 vial	28 days after the initial dose	\$28.39 for dates of service prior to 3/15/2021 ; \$40.00 for dates of service through

	(Second Dose)	disease [COVID-19] vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; second dose	80777-0273-99 carton		8/8/2021 ; \$83.00 for dates of service 8/9/2021 and after.
0013A	Moderna Covid-19 Vaccine Administration (Third Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19] vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	80777-0273-10 vial	CDC recommended population 28 or more days after second dose	\$83.00 for dates of service 08/12/2021 and after
91306	Moderna COVID-19 Vaccine	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19] vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	80777-0273-10		\$.00
0064A	Moderna COVID-19 Vaccine (Booster)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19] vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose	80777-0273-10	Refer to FDA/CDC Guidance	\$83.00 for dates of service 10/29/2021 and after
91309	Moderna COVID-19 Vaccine	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19] vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	80777-0275-05		\$.00
0091A	Moderna COVID-19 Vaccine (First Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19] vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when	80777-0275-05		\$83.00 for dates of service 06/17/2022 and after

		administered to individuals 6 through 11 years			
0092A	Moderna COVID-19 Vaccine (Second Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose, when administered to individuals 6 through 11 years	80777-0275-05	1st Dose to 2nd Dose: 1 Month	\$83.00 for dates of service 06/17/2022 and after
0093A	Moderna COVID-19 Vaccine (Third Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose, when administered to individuals 6 through 11 years	80777-0275-05	2nd Dose to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]): 1 Month	\$83.00 for dates of service 06/17/2022 and after
0094A	Moderna COVID-19 Vaccine (Booster)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, booster dose	80777-0275-05	Refer to FDA/CDC Guidance	\$83.00 for dates of service 03/29/2022 and after
91311	Moderna COVID-19 Vaccine	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	80777-0279-05		\$.00
0111A	Moderna COVID-19 Vaccine (First Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25	80777-0279-05		\$83.00 for dates of service 06/17/2022 and after

		mcg/0.25 mL dosage; first dose			
0112A	Moderna COVID-19 Vaccine (Second dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose	80777-0279-05	1st Dose to 2nd Dose: 1 Month	\$83.00 for dates of service 06/17/2022 and after
0113A	Moderna COVID-19 Vaccine (Third dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; third dose	80777-0279-05	2nd Dose to 3rd Dose (CDC recommended population[s] [eg, immunocompromised]): 1 Month	\$83.00 for dates of service 06/17/2022 and after
91313	Moderna COVID-19 Vaccine, Bivalent (Booster)	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	80777-0282-05		\$.00
0134A	Moderna COVID-19 Vaccine, Bivalent (Booster)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA LNP, spike protein, bivalent, preservative free, 50 mcg/0.5 mL dosage, booster dose	80777-0282-05	Refer to FDA/CDC Guidance	\$83.00 for dates of service 08/31/2022 and after
91314	Moderna COVID-19 Vaccine, Bivalent	Severe acute respiratory syndrome coronavirus 2 (SARS -CoV -2) (coronavirus disease [COVID -19]) vaccine, mRNA -LNP, spike protein, bivalent, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	80777-0282-05		\$.0Refer to FDA/CDC Guidance0

0144A	Moderna COVID-19 Vaccine, Bivalent	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNLNP, spike protein, bivalent, preservative free, 25 mcg/0.25 ml dosage, booster dose	80777-0282-05	Refer to FDA/CDC Guidance	\$83.00 for dates of service 08/31/2022 and after
91303	Janssen COVID-19 Vaccine (Booster)	Severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5mL dosage, for intramuscular use	59676-0580-05 59676-0580-15 carton		\$.00
0031A	Janssen COVID-19 Vaccine Administration (Single Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage, single dose	59676-0580-05 59676-0580-15 carton		\$28.39 for dates of service prior to 3/15/2021 ; \$40.00 for dates of service through 8/8/2021 ; \$83.00 for dates of service 8/9/2021 and after.
0034A	Janssen COVID-19 Vaccine Administration (Booster Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 ¹⁰ viral particles/0.5 mL dosage, booster	59676-0580-05 59676-0580-15 carton	Refer to FDA/ CDC guidance	\$83.00 for dates of service 10/20/2021 and after
91304	Novavax COVID-19 Vaccine	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5 mL dosage, for intramuscular use	80631-1000-01		\$0.00

0041A	Novavax COVID-19 Vaccine (First Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; first dose	80631-1000-01		\$83.00 for dates of service 07/13/2022 and after
0042A	Novavax COVID-19 Vaccine (Second Dose)	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, recombinant spike protein nanoparticle, saponin-based adjuvant, preservative free, 5 mcg/0.5mL dosage; second dose	80631-1000-01		\$83.00 for dates of service 07/13/2022 and after

Billing Example 1500 - Professional Claim

24. A	B	C	D	E	F	G	H	I	J
Dates of Service	Place of Service	EMG	Procedure, Services or Supplies	Diagnosis Pointer	\$ Charges	Days or Units	EPSDT/Family Planning	ID Qual	Rendering Provider
12/15/2020 - 12/15/2020	11	N	91300	A	0.00	1		XX	123456789
12/15/2020 - 12/15/2020	11	N	0001A	A	16.94	1		XX	123456789

01/04/2021 - 01/04/2021	11	N	0002A	A	28.39	1		XX	123456789
----------------------------	----	---	-------	---	-------	---	--	----	-----------

Pharmacies and other providers may bill both administration fees on a single claim after both vaccines have been administered or separate claims may be submitted as each vaccine administration is completed.

Pharmacy Point-of Sale Processing for COVID-19 Administration Fees

The pharmacy must follow the NCPDP billing guidance as noted below.

Billing for reimbursement of a free product (no associated cost) including an administration fee per NCPDP guidelines:

- The submitted Transaction Code (103-A3) is a “B1” (Claim Billing).
- The submitted Prescription/Service Reference Number Qualifier (455-EM) is a “1” (Rx Billing).
- The claim pricing segment follows the prescription claim request formula.
- The Product/Service ID (407-D7) should be submitted with the correct
- Product/Service ID Qualifier (436/E1) (in this example “03” (NDC))
- Product/Service ID (407-D7) contains the NDC Number of the vaccine or other product that was administered and obtained at zero cost.
- The Days’ Supply (405-D5) should be submitted with a value of “1”.
- The Quantity Dispensed (442-E7) should be submitted with the value that represents the quantity of drug product administered.
- The DUR/PPS Segment, with a “MA” (Medication Administered) in the Professional Service Code (440-E5), is submitted to identify the product was administered.
- The Incentive Amount Submitted (438-E3) is submitted to identify the pharmacy is seeking reimbursement for the administration of the product.
- The submission clarification code (420-DK)
 - Initial Dose(s) and Single Dose: Submission Clarification Code of **2 “Other Override”** - defined as “Used when authorized by the payer in business cases not currently addressed by other SCC values to indicate the first dose of a multi-dose vaccine is being administered”
 - Final Dose: Submission Clarification Code of **6 “Starter Dose”** - defined as “The pharmacist is indicating that the previous medication was a starter dose and now additional medication is needed to continue treatment to indicate the second dose of a multi-dose vaccine is being administered”

- **The administration fee amount is as follows for vaccine requiring two doses:**

Dates of service **12/14/2020 through 3/14/2021**

- § Initial Dose: \$16.94
- § Final Dose: \$28.39
- § Single Dose: \$28.39

Dates of service on and after **3/15/2021 through 8/8/2021**

- § Initial Dose: \$40.00
- § Final Dose: \$40.00
- § Single Dose: \$40.00

Dates of service **8/9/2021 and after**

- § Initial Dose: \$83.00
- § Final Dose: \$83.00

- § Single Dose: \$83.00
 - § Booster Dose: \$83.00
- Basis of Cost Determination (423-DN) should be submitted with the value “15” (Free product or no associated cost).